New Delhi [India], October 28 (ANI): The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, has released a list of 543 brands of anti-cancer medicines with their revised Maximum Retail Price (MRP).
As per the release, the revised MRPs will be effective from November 9. The revised price list reflects the information submitted by companies up to Tuesday, and it will be updated as and when manufacturers submit their revised prices of non-scheduled anti-cancer drugs.
Among the medicines listed, Anastrozole 1 mg tablets sold under the brand name Anarzole by RPG Life Sciences Ltd saw its MRP reduced from Rs 695.76 for a pack of 10 tablets to Rs 73.
Azacitidine 100 mg injection, marketed as Azacytin by Dr. Reddy’s Laboratories Limited, recorded a price reduction from Rs 6,337 to Rs 1,495.04 for a pack of one.
Bevacizumab 100 mg/4 ml injection, sold under the brand name Bevacizab by Abbott Healthcare Pvt. Ltd., saw its MRP revised from Rs 21,767.70 to Rs 5,930.13 for a 4 ml vial.
Dasatinib 20 mg tablets, marketed as Dasanat 20 by Natco Pharma Limited, recorded a reduction from Rs 2,812.50 to Rs 1,085.93 for a pack of 60 tablets.
RPG Life Sciences Ltd also reported revised prices for Denosumab and Enzalutamide. Denosumab 60 mg injection, sold as Debrumab 60 mg in a 1 ml pre-filled syringe, saw its MRP reduced from Rs 22,031.25 to Rs 5,941. Enzalutamide 40 mg capsules, marketed as Enuta in a pack of 28 capsules, recorded a reduction from Rs 6,578.20 to Rs 2,232.
Meanwhile, Erlotinib 150 mg tablets, sold under the brand name Erlib by Neon Laboratories Limited in a bottle of 30 tablets, saw their MRP reduced from Rs 4,637.45 to Rs 2,008.
Fludarabine 50 mg injection, marketed as Fludanox by Hetero Healthcare Ltd, recorded a price revision from Rs 14,235 to Rs 2,432 per vial.
Fulvestrant 50 mg injection, sold under the brand name Fulbreca by RPG Life Sciences Ltd in a 5 ml vial, saw its MRP reduced from Rs 26,072.16 to Rs 5,491.
On October 17, NPPA had announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs in the public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines. Manufacturers were instructed to submit their revised list to NPPA.
The 137 non-scheduled anti-cancer drugs include immunotherapy medicines used in the treatment of over 20 types of cancer, Denosumab used by breast and prostate cancer patients, Pegfilgrastim used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers. (ANI)
Related reading
